Latest News

Updated HHS Pediatric Antiretroviral Therapy Guidelines Released

By Estela Balderas | April 16, 2022

April 12, 2022: The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) has reviewed the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Key updates are summarized below:The U.S. Food and Drug Administration (FDA) recently approved long-acting injectable cabotegravir and rilpivirine (Cabenuva) for use in children and adolescents…

READ MORE

Update to COVID-19 Treatment Guidelines: Changes Affecting People with HIV

By Estela Balderas | February 18, 2022

February 7, 2022:  The COVID-19 Treatment Guidelines Panel (the Panel) has published a revised version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. The Panel periodically publishes statements that provide up-to-date guidance for clinicians on various aspects of COVID-19 treatment. During this update, the information and recommendations from several recently published statements were incorporated into the…

READ MORE

Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

By Estela Balderas | February 18, 2022

February 17, 2022: The Panel updated the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Highlights from the updated section are summarized below:  Mycobacterium tuberculosis Updated references and rationales. Updated drug–drug interactions. Recommended short-course, rifamycin-based, latent tuberculosis infection (LTBI) treatment regimens (3HP and 3HR) over longer isoniazid monotherapy. Clarified that, for the…

READ MORE

FDA Approves First Injectable Treatment for #HIV Pre-Exposure Prevention (PrEP)

By Estela Balderas | February 4, 2022

On December 10, 2021, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. Apretude is given first as two initiation injections administered one month apart, and then every…

READ MORE

Updates to Perinatal HIV Clinical Guidelines

By Estela Balderas | February 4, 2022

January 5, 2022: The Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission recently updated several sections of the Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. The following sections were among those updated: Maternal HIV Testing and Identification of Perinatal…

READ MORE

Updates to the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV

By Estela Balderas | February 4, 2022

This notice updates and corrects an announcement on this subject sent January 20, 2022. The Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) updated the following sections of the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Highlights are summarized below: Early (Acute and Recent) HIV Infection…

READ MORE

#HIV Alert: Updated HIV PrEP Guidelines

By Estela Balderas | December 10, 2021

December 8, 2021: Today, the Centers for Disease Control and Prevention (CDC) published its updated Clinical Practice Guideline for Preexposure Prophylaxis for HIV Prevention and Clinical Providers Supplement. The updated guideline and supplement reflect the latest science and are intended to help physicians effectively prescribe all FDA-approved pre-exposure prophylaxis (PrEP) medications to patients and increase PrEP use among all…

READ MORE

Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

By Estela Balderas | November 20, 2021

November 18, 2021: The Panel updated the following sections of the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Highlights from the sections are summarized below:  Appendix B: Panel Roster and Financial Disclosures:   Updated member conflict of interest information for 2021-2022.Updated roster to include 22 new members, 6 new Section…

READ MORE

Hiring! Project Director, MATEC Regional Headquarters

By Estela Balderas | November 17, 2021

MATEC is hiring a Project Director at our Regional Headquarters located at the University of Illinois College of Medicine at Chicago, Department of Family and Community Medicine. The Project Director oversees the day-to-day management of the MATEC program. This position provides leadership and management of the program while working closely with the Principal Investigator, Medical…

READ MORE

MATEC Missouri is hiring! Regional Instructional Design Coordinator.

By Estela Balderas | September 30, 2021

Regional Instructional Design Coordinator Remote work opportunity! The MATEC (Midwest AIDS Training + Education Center) Regional Instructional Design Coordinator is responsible for leading regional MATEC efforts to deliver state-of-the-art distance-based trainings. This position will involve collaboration and communication with all other MATEC sites across the region as well as within the MATEC-Missouri team. This position…

READ MORE

CONNECT WITH US

MATEC Regional Headquarters
University of Illinois at Chicago, College of Medicine
Department of Family and Community Medicine
1919 W. Taylor Street (MC779), 8th Floor
Chicago IL 60612